Literature DB >> 3932466

Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation.

M J Weinstein, L E Chute, G W Schmitt, R H Hamburger, K A Bauer, J H Troll, P Janson, D Deykin.   

Abstract

Factor VIII antigen (VIII:CAg) exhibits molecular weight heterogeneity in normal plasma. We have compared the relative quantities of VIII:CAg forms present in normal individuals (n = 22) with VIII:CAg forms in renal dysfunction patients (n = 19) and in patients with disseminated intravascular coagulation (DIC; n = 7). In normal plasma, the predominant VIII: CAg form, detectable by sodium dodecyl sulfate polyacrylamide gel electrophoresis, was of molecular weight 2.4 X 10(5), with minor forms ranging from 8 X 10(4) to 2.6 X 10(5) D. A high proportion of VIII:CAg in renal dysfunction patients, in contrast, was of 1 X 10(5) mol wt. The patients' high 1 X 10(5) mol wt VIII: CAg level correlated with increased concentrations of serum creatinine, F1+2 (a polypeptide released upon prothrombin activation), and with von Willebrand factor. Despite the high proportion of the 1 X 10(5) mol wt VIII:CAg form, which suggests VIII:CAg proteolysis, the ratio of Factor VIII coagulant activity to total VIII:CAg concentration was normal in renal dysfunction patients. These results could be simulated in vitro by thrombin treatment of normal plasma, which yielded similar VIII:CAg gel patterns and Factor VIII coagulant activity to antigen ratios. DIC patients with high F1+2 levels but no evidence of renal dysfunction had an VIII:CAg gel pattern distinct from renal dysfunction patients. DIC patients had elevated concentrations of both the 1 X 10(5) and 8 X 10(4) mol wt VIII:CAg forms. We conclude that an increase in a particular VIII:CAg form correlates with the severity of renal dysfunction. The antigen abnormality may be the result of VIII:CAg proteolysis by a thrombinlike enzyme and/or prolonged retention of proteolyzed VIII:CAg fragments.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932466      PMCID: PMC424088          DOI: 10.1172/JCI112117

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity.

Authors:  S I RAPAPORT; S SCHIFFMAN; M J PATCH; S B AMES
Journal:  Blood       Date:  1963-02       Impact factor: 22.113

2.  Electroimmuno assay.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

3.  The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity.

Authors:  C T Esmon
Journal:  J Biol Chem       Date:  1979-02-10       Impact factor: 5.157

4.  Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences.

Authors:  A P Laudano; R F Doolittle
Journal:  Biochemistry       Date:  1980-03-04       Impact factor: 3.162

5.  Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure.

Authors:  R P Warrell; M B Hultin; B S Coller
Journal:  Am J Med       Date:  1979-02       Impact factor: 4.965

6.  Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.

Authors:  M Weinstein; L Chute; D Deykin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

7.  Preparation and properties of bovine factor VIII (antihemophilic factor).

Authors:  G A Vehar; E W Davie
Journal:  Biochemistry       Date:  1980-02-05       Impact factor: 3.162

8.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.

Authors:  J M Teitel; K A Bauer; H K Lau; R D Rosenberg
Journal:  Blood       Date:  1982-05       Impact factor: 22.113

9.  Treatment of the bleeding tendency in uremia with cryoprecipitate.

Authors:  P A Janson; S J Jubelirer; M J Weinstein; D Deykin
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin.

Authors:  M B Hultin; J Jesty
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.